Cargando…

A European project on incidence, treatment, and outcome of sarcoma

BACKGROUND: Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues and viscera. Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of origin, the incidence of sarcoma is grossly underestimated. The rar...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrangelo, Giuseppe, Fadda, Emanuela, Cegolon, Luca, Montesco, Maria C, Ray-Coquard, Isabel, Buja, Alessandra, Fedeli, Ugo, Frasson, Alvise, Spolaore, Paolo, Rossi, Carlo R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882909/
https://www.ncbi.nlm.nih.gov/pubmed/20384990
http://dx.doi.org/10.1186/1471-2458-10-188
_version_ 1782182216816656384
author Mastrangelo, Giuseppe
Fadda, Emanuela
Cegolon, Luca
Montesco, Maria C
Ray-Coquard, Isabel
Buja, Alessandra
Fedeli, Ugo
Frasson, Alvise
Spolaore, Paolo
Rossi, Carlo R
author_facet Mastrangelo, Giuseppe
Fadda, Emanuela
Cegolon, Luca
Montesco, Maria C
Ray-Coquard, Isabel
Buja, Alessandra
Fedeli, Ugo
Frasson, Alvise
Spolaore, Paolo
Rossi, Carlo R
author_sort Mastrangelo, Giuseppe
collection PubMed
description BACKGROUND: Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues and viscera. Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of origin, the incidence of sarcoma is grossly underestimated. The rarity of the disease and the variety of histological types (more than 70) or locations account for the difficulty in acquiring sufficient personal experience. In view of the above the European Commission funded the project called Connective Tissues Cancers Network (CONTICANET), to improve the prognosis of sarcoma patients by increasing the level of standardization of diagnostic and therapeutic procedures through a multicentre collaboration. METHODS/DESIGN: Two protocols of epidemiological researches are here presented. The first investigation aims to build the population-based incidence of sarcoma in a two-year period, using the new 2002 WHO classification and the "second opinion" given by an expert regional pathologist on the initial diagnosis by a local pathologist. A three to five year survival rate will also be determined. Pathology reports and clinical records will be the sources of information. The second study aims to compare the effects on survival or relapse-free period - allowing for histological subtypes, clinical stage, primary site, age and gender - when the disease was treated or not according to the clinical practice guidelines (CPGs). DISCUSSION: Within CONTICANET, each group was asked to design a particular study on a specific objective, the partners of the network being free to accept or not the proposed protocol. The first protocol was accepted by the other researchers, therefore the incidence of sarcoma will be assessed in three European regions, Rhone-Alpes and Aquitaine (France) and Veneto (Italy), where the geographic distribution of sarcoma will be compared after taking into account age and gender. The conformity of the clinical practice with the recommended guidelines will be investigated in a French (Rhone Alps) and Italian (Veneto) region since the CPGs were similar in both areas.
format Text
id pubmed-2882909
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28829092010-06-10 A European project on incidence, treatment, and outcome of sarcoma Mastrangelo, Giuseppe Fadda, Emanuela Cegolon, Luca Montesco, Maria C Ray-Coquard, Isabel Buja, Alessandra Fedeli, Ugo Frasson, Alvise Spolaore, Paolo Rossi, Carlo R BMC Public Health Study protocol BACKGROUND: Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues and viscera. Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of origin, the incidence of sarcoma is grossly underestimated. The rarity of the disease and the variety of histological types (more than 70) or locations account for the difficulty in acquiring sufficient personal experience. In view of the above the European Commission funded the project called Connective Tissues Cancers Network (CONTICANET), to improve the prognosis of sarcoma patients by increasing the level of standardization of diagnostic and therapeutic procedures through a multicentre collaboration. METHODS/DESIGN: Two protocols of epidemiological researches are here presented. The first investigation aims to build the population-based incidence of sarcoma in a two-year period, using the new 2002 WHO classification and the "second opinion" given by an expert regional pathologist on the initial diagnosis by a local pathologist. A three to five year survival rate will also be determined. Pathology reports and clinical records will be the sources of information. The second study aims to compare the effects on survival or relapse-free period - allowing for histological subtypes, clinical stage, primary site, age and gender - when the disease was treated or not according to the clinical practice guidelines (CPGs). DISCUSSION: Within CONTICANET, each group was asked to design a particular study on a specific objective, the partners of the network being free to accept or not the proposed protocol. The first protocol was accepted by the other researchers, therefore the incidence of sarcoma will be assessed in three European regions, Rhone-Alpes and Aquitaine (France) and Veneto (Italy), where the geographic distribution of sarcoma will be compared after taking into account age and gender. The conformity of the clinical practice with the recommended guidelines will be investigated in a French (Rhone Alps) and Italian (Veneto) region since the CPGs were similar in both areas. BioMed Central 2010-04-12 /pmc/articles/PMC2882909/ /pubmed/20384990 http://dx.doi.org/10.1186/1471-2458-10-188 Text en Copyright ©2010 Mastrangelo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study protocol
Mastrangelo, Giuseppe
Fadda, Emanuela
Cegolon, Luca
Montesco, Maria C
Ray-Coquard, Isabel
Buja, Alessandra
Fedeli, Ugo
Frasson, Alvise
Spolaore, Paolo
Rossi, Carlo R
A European project on incidence, treatment, and outcome of sarcoma
title A European project on incidence, treatment, and outcome of sarcoma
title_full A European project on incidence, treatment, and outcome of sarcoma
title_fullStr A European project on incidence, treatment, and outcome of sarcoma
title_full_unstemmed A European project on incidence, treatment, and outcome of sarcoma
title_short A European project on incidence, treatment, and outcome of sarcoma
title_sort european project on incidence, treatment, and outcome of sarcoma
topic Study protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882909/
https://www.ncbi.nlm.nih.gov/pubmed/20384990
http://dx.doi.org/10.1186/1471-2458-10-188
work_keys_str_mv AT mastrangelogiuseppe aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT faddaemanuela aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT cegolonluca aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT montescomariac aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT raycoquardisabel aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT bujaalessandra aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT fedeliugo aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT frassonalvise aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT spolaorepaolo aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT rossicarlor aeuropeanprojectonincidencetreatmentandoutcomeofsarcoma
AT mastrangelogiuseppe europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT faddaemanuela europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT cegolonluca europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT montescomariac europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT raycoquardisabel europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT bujaalessandra europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT fedeliugo europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT frassonalvise europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT spolaorepaolo europeanprojectonincidencetreatmentandoutcomeofsarcoma
AT rossicarlor europeanprojectonincidencetreatmentandoutcomeofsarcoma